Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy-Reference-Cited by-同舟云学术

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

Published:2018-10 Issue:8 Volume:119 Page:950-960
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Fumet Jean-David,Richard Corentin,Ledys Fanny,Klopfenstein Quentin,Joubert Philippe,Routy Bertrand,Truntzer Caroline,Gagné Andréanne,Hamel Marc-André,Guimaraes Camila Figueiredo,Coudert Bruno,Arnould Laurent,Favier Laure,Lagrange Aurélie,Ladoire Sylvain,Saintigny Pierre,Ortiz-Cuaran Sandra,Perol Maurice,Foucher Pascal,Hofman Paul,Ilie Marius^ORCID,Chevrier Sandy,Boidot Romain,Derangere Valentin,Ghiringhelli François

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0220-9.pdf

Reference46 articles.

1. Didkowska, J., Wojciechowska U., Mańczuk M., Łobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med [Internet]. avr 2016 [cité 26 juin 2017];4(8). Disponible sur: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860480/

2. Donnem, T. et al. Stromal CD8+ T-cell density—a promising supplement to TNM staging in non–small cell lung cancer. Clin. Cancer Res. 21, 2635–2643 (2015).

3. Gatalica, Z. et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol. Prev. Biomark. 23, 2965–2970 (2014).

4. Azoury, S. C., Straughan D. M., and Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 15, 452–62 (2015).

5. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer;npj Precision Oncology;2024-01-31

2. Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study;Frontiers in Oncology;2024-01-26

3. Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types;PLOS Genetics;2024-01-19

4. Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach;Biomedicines;2024-01-18

5. Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC;Translational Oncology;2024-01